Description: Advanced Solid Tumors: ABBV-400 as Monotherapy-A Global First-in-Human Study
Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload
Target Patient Population: All solid tumors
Study Design: Study drug is administered IV every 3 weeks
For more information on this trial, read its profile on clinicaltrials.gov here.